CBD has been used in recent years to treat a variety of health conditions and ailments. From insomnia to anxiety and through to chronic pain, CBD offers natural relief to many people.
CBD is also an antiseptic, it contains anti-bacterial properties and is believed to be useful in the treatment of gum disease. Impression Healthcare, an Australian-based medical cannabis company, has just been approved for a Phase 2a Clinical Trial looking at how CBD mouthwashes and toothpaste could potentially be used to fight gum disease.
The trial intends to look at how CBD could fight conditions such as Gingivitis and Periodontitis. The study taking place in Australia is a collaboration between Impression and AXIM Biotechnologies Inc. AXIM is a pharmaceutical-grade medical cannabis producer in the US who are supplying the various CBD toothpaste and mouthwashes for the trial.
As Joel Latham, CEO at Impression said in a statement to Times of CBD, “Formal registration of the gingivitis and periodontitis trial represents significant progress in IHL’s medicinal cannabis activities and is the culmination of many months of work by our team and research partners.
“We are excited to have assembled highly qualified researchers for a world-first trial for the use of CBD in treatment of Gingivitis and Gum Disease, which are major problems representing a major market.”
Research carried out recently by another Australian cannabis firm called Botanix, indicated that CBD has strong antibiotic properties and even kills some bacteria which have become resistant to prescription antibiotics.
According to Impression, if the Australian Special Access Scheme (for medical cannabis) can be convinced that CBD contains anti-inflammatory and antibiotic properties, it could meet the stringent criteria of “Category B.” If that happens, dentists and doctors alike could prescribe a natural CBD for gum disease instead of a pharmaceutical one.
As Latham added, “We are confident that the quality of the trial will supply the requisite peer-reviewed data for unique product sales under the SAS and will further develop commercialization opportunities for our products in this field.”
The current trial is one of four studies looking into CBD. The other three trials are also interesting as they will look at the potential of CBD to help with a concussion, sleep apnea, and temporomandibular disorders, which is the joint that connects the jaw to the skull.
While the outcomes of the current research underway remain to be seen, previous studies have demonstrated a connection for CBD as an anti-inflammatory and antibiotic. If the Clinical Trials are a success, it could become a matter of course for CBD toothpaste and mouthwash to be prescribed for mouth diseases instead of often toxic and even addictive pharmaceutical alternatives.
